Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
India · Delayed Price · Currency is INR 2,032.80
+2.30 (0.11%)
Oct 31, 2025, 3:30 PM IST
Caplin Point Laboratories Revenue
Caplin Point Laboratories had revenue of 5.10B INR in the quarter ending June 30, 2025, with 11.17% growth. This brings the company's revenue in the last twelve months to 19.89B, up 13.14% year-over-year. In the fiscal year ending March 31, 2025, Caplin Point Laboratories had annual revenue of 19.40B with 14.35% growth.
Revenue (ttm)
19.89B
Revenue Growth
+13.14%
P/S Ratio
7.77
Revenue / Employee
5.01M
Employees
3,966
Market Cap
154.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 19.40B | 2.43B | 14.35% |
| Mar 31, 2024 | 16.96B | 2.28B | 15.51% |
| Mar 31, 2023 | 14.68B | 1.97B | 15.53% |
| Mar 31, 2022 | 12.71B | 2.09B | 19.64% |
| Mar 31, 2021 | 10.62B | 1.98B | 22.96% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 279.66B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |
Caplin Point Laboratories News
- 2 months ago - Caplin Point subsidiary gets USFDA nod for Milrinone Lactate in 5% Dextrose Injection - Business Upturn
- 3 months ago - Caplin Point shares surge 5% as Q1 revenue jumps 11% YoY to Rs 510 crore, net profit up 23.2% YoY - Business Upturn
- 5 months ago - Caplin Point subsidiary to acquire Mexican pharma firm Triwin Pharma S.A. DE C.V. - Business Upturn
- 6 months ago - Caplin Point Q4 results: Revenue up 10.9% YoY to Rs 502.45 crore, Net profit rises 19.8% YoY - Business Upturn
- 6 months ago - Caplin Point Laboratories subsidiary receives USFDA approval for Haloperidol Decanoate Injection - Business Upturn
- 6 months ago - Caplin Point subsidiary Caplin Steriles gets USFDA approval for Phytonadione Injectable Emulsion - Business Upturn
- 7 months ago - Caplin Point Laboratories shares jump over 3% after acquiring Neoethicals Chile SpA - Business Upturn
- 8 months ago - Caplin Point subsidiary secures USFDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution - Business Upturn